AHS 2022 | Discontinuation of anti-CGRP antibodies in non-responders

Stewart Tepper, MD, Dartmouth-Hitchcock Medical Center, Lebanon, NH, discusses a study that investigated how long individuals should maintain anti-CGRP monoclonal antibodies as a treatment before discontinuation. Many European countries have regulatory requirements to stop therapy if the mean monthly migraine frequency is not reduced by a certain threshold after 3-6 months. The study showed that if patients who had no response after two months of treatment were maintained for five months, the response rate increased. With this being the case for many anti-CGRP monoclonal antibodies, patients should be kept on treatment for at least five to six months before evaluating efficacy. This interview took place at the 2022 American Headache Society (AHS) Meeting in Denver, CO.